

## In This Issue

#### PAGE 2

#### **Calendar of Events**

#### PAGE 5

#### **Nephrology and Dialysis**

Hemodialysis Catheter Market expected to reach \$1.9 billion by 2034

Systemic barriers in pre-dialysis care drive vascular access disparities for Hispanic hemodialysis patients

SIR updates guidance for percutaneous arteriovenous fistula creation for dialysis access

#### PAGE 6

Al-driven tools found to enhance nephrology care in patient outcomes

New questionnaire helps chronic kidney disease patients track symptoms more effectively

Renal insufficiency market projected to reach \$72.4B by 2034 driven by drug innovation

#### PAGE 7

Generative AI transforms dialysis care with first PHI-compliant platform

New \$100,000 fee and entry restrictions for H-1B workers: What employers need to know now

Plasma exchange linked to improved dialysis outcomes in AAV patients

#### PAGE 8

Kidney dialysis equipment market set for strong growth driven by chronic kidney disease, technological innovation

#### **VAC, ASC and Office-Based Labs**

Quanta and Innovative Renal Care sign multiyear agreement to expand access to advanced dialysis system

#### PAGE 9

Florida plan to end vaccine mandates raises legal public health concerns

Renalytix partners with Tempus to expand access to kidneyintelX.dkd testing for CKD patients with type 2 diabetes

Cigna Temporarily Pauses Its E/M Coding and Accuracy Policy (R49)

#### PAGE 10

OIG and DOJ Intensify Remote Patient Monitoring Oversight: 2025 Data Snapshot, FCA Settlement and the Emerging Enforcement Playbook

CMS's IOTA Model Took Effect July 1, 2025: Implications for Transplant Hospitals and Nephrology Stakeholders

#### **PAGE 11**

#### **Benesch Insights**

Jason Greis featured on Wealth Planning for the Modern Physician Podcast "How Practices Can Build the Right Physician Comp Models Today and Beyond"



information regarding our upcoming events or if you'd like to guest author an article for this newsletter.

sdowning@beneschlaw.com jgreis@beneschlaw.com jcilek@beneschlaw.com

#### Calendar of Events

NOVEMBER 3-4, 2025

Becker's 4th Annual Fall 2025 Payers **Issue Roundtable** 

Chicago, IL

For more information, please click here.

NOVEMBER 3-6, 2025

**Becker's Healthcare: 13th Annual CEO + CFO Roundtable** 

Chicago, IL

For more information, please click here.

NOVEMBER 5-9, 2025

**ASN: Kidney Week 2025** 

Houston, TX

(Call for Abstracts Deadline May 21) For more information, please click <u>here</u>.

**NOVEMBER 12, 2025** 

**RPA PM EDGE: Keeping Nephrology Practice Managers Educated &** 

**Empowered** 

For more information, please click here.

MARCH 1-4, 2026

**American Venous Forum 2026** 

Denver, CO

For more information, please click here.

MARCH 19-21, 2026

2026 OEIS Scientific Meeting

Las Vegas, NV (details to come)

APRIL 16-19, 2026

**RPA 2026 Annual Meeting** 

Atlanta, GA

For more information, please click here.

OCTOBER 21-25, 2026

**ASN: Kidney Week 2026** 

Denver, CO

For more information, please click here.



### Calendar of Events (cont'd)

**Dialysis & Nephrology** DIGEST







\$249.00 RPA \$299.00 Non-**Member Price for Member Price for** 3 webinars! 3 webinars! **Renal Physicians Association Keeping Nephrology Practice Managers Educated & Empowered** 





## Nephrology and Dialysis

SEPTEMBER 3, 2025

#### Hemodialysis Catheter Market expected to reach \$1.9 billion by 2034

The global hemodialysis catheter market is projected to reach \$1.9 billion by 2034, driven by the rising prevalence of chronic kidney disease (CKD) and end-stage renal disease (ESRD). Hemodialysis catheters are essential for providing life-saving dialysis treatment to millions of patients worldwide. Market growth is fueled by increasing demand for advanced catheters that offer improved durability, reduced infection risk and enhanced patient comfort. Technological advancements in catheter design and materials are expected to further support market expansion and improve health outcomes for dialysis patients.

Source: Exactitude Consultancy

SEPTEMBER 5, 2025

### Systemic barriers in pre-dialysis care drive vascular access disparities for Hispanic hemodialysis patients

A recent JAMA Network Open study highlights how gaps in pre-dialysis nephrology care contribute to vascular access inequities among Hispanic patients starting hemodialysis. Researchers found that delayed specialist referrals account for roughly one-third of disparities in fistula and graft placement, increasing reliance on high-risk central venous catheters. The study emphasizes that systemic factors, rather than patient behavior alone, limit timely access to optimal dialysis preparation. Authors call for policy-driven reforms, culturally competent outreach and multidisciplinary care models to improve early nephrology engagement, enhance vascular access outcomes and reduce preventable complications, advancing equity in kidney failure care.

Source: Bioengineer

SEPTEMBER 9, 2025

### SIR updates guidance for percutaneous arteriovenous fistula creation for dialysis access

The Society of Interventional Radiology (SIR) released updated guidance for percutaneous arteriovenous fistula (pAVF) creation for dialysis access, published in the Journal of Vascular and Interventional Radiology. The guidance outlines program development, patient preparation, procedural steps, complication management and follow-up care. SIR President Robert A. Lookstein emphasized that durable hemodialysis fistulas reduce morbidity and enhance quality of life for end-stage renal disease patients.

Source: Society of Interventional Radiology



#### Nephrology and Dialysis (cont'd)

SEPTEMBER 12, 2025

#### Al-driven tools found to enhance nephrology care in patient outcomes

Al-driven solutions are transforming nephrology and dialysis care by enhancing diagnosis, optimizing treatment plans and improving patient outcomes for CKD, AKI and ESRD patients. Federated learning enables collaborative AI model development across multiple hospitals while maintaining patient privacy and regulatory compliance. Al tools provide real-time feedback on lifestyle, medication adherence and symptom tracking, empowering patients and bridging language and literacy gaps, especially for vulnerable populations. Al also supports transplant specialists in organ matching and immunosuppressive therapy optimization, leading to better transplant success rates and postoperative outcomes.

Source: Healthcare Tech Outlook

SEPTEMBER 15, 2025

### New questionnaire helps chronic kidney disease patients track symptoms more effectively

Researchers led by Professor Derek Kyte developed the Kidney Symptom Burden Questionnaire (KSB-Q), a nine-question tool designed to capture the most burdensome symptoms experienced by people with chronic kidney disease (CKD), including fatigue, pain, sleep disturbances and shortness of breath. Tested in over 400 patients across CKD stages, the KSB-Q takes approximately five minutes to complete and can be used in both clinical and research settings. By streamlining symptom reporting, the tool supports more personcentered care, enabling earlier interventions and better communication between patients and healthcare providers. Future digital adaptations will further personalize monitoring.

Source: Kidney Research UK

SEPTEMBER 18, 2025

## Renal insufficiency market projected to reach \$72.4B by 2034 driven by drug innovation

The global renal insufficiency market, valued at \$41.2 billion in 2024, is expected to reach \$72.4 billion by 2034, expanding at a CAGR of 5.7%. Growth is driven by the rising global prevalence of chronic kidney disease (CKD), largely linked to diabetes, hypertension, obesity and aging populations. Expanding adoption of innovative drug classes such as SGLT2 inhibitors (dapagliflozin, empagliflozin) and non-steroidal MRAs (finerenone) is reshaping treatment strategies, while advances in dialysis technology, transplantation and regenerative medicine provide critical options for advanced-stage patients. Al-powered diagnostic and monitoring tools are emerging as key enablers for early detection and patient management. Regionally, North America leads due to advanced infrastructure and reimbursement policies, while Asia-Pacific is the fastest-growing market with a CAGR of 7.1%, fueled by high CKD burden and government initiatives.

Source: Exactitude Consultancy



#### Nephrology and Dialysis (cont'd)

**SEPTEMBER 19, 2025** 

## Generative AI transforms dialysis care with first PHI-compliant platform

Generative AI is emerging as a powerful tool in healthcare, extending beyond diagnostics into patient management and operational efficiency. In dialysis care, where patient adherence is critical for survival, Nikitha Edulakanti developed the first PHI-compliant generative AI system for continuity of care, overcoming one of the field's toughest challenges: integrating advanced Al into regulated healthcare environments. Her platform extracts and structures unorganized patient data, from treatment histories to physician notes, and generates real-time insights that flag early signs of disengagement. This proactive approach enables care teams to intervene before patients miss treatments, reducing hospitalizations and improving outcomes. In its first year, the system prevented patient drop-offs, saved significant healthcare costs, and boosted safety across a kidney care network.

Source: The American Reporter

SEPTEMBER 21, 2025

## New \$100,000 fee and entry restrictions for H-1B workers: What employers need to know now

A new presidential proclamation imposes a \$100,000 fee on employers sponsoring H-1B workers entering the U.S. for the first time, with the rule applying only to petitions filed after Sept. 21, 2025. Current H-1B employees and approved petitions are not affected. The steep new cost and heightened scrutiny create financial and operational risks for employers relying on global talent, especially those planning to hire workers from abroad.

Source: Benesch

**SEPTEMBER 22, 2025** 

### Plasma exchange linked to improved dialysis outcomes in AAV patients

A French study published in Kidney International Reports found that about half of patients who started dialysis due to ANCA-associated vasculitis (AAV) were able to discontinue dialysis within a year. The likelihood of stopping dialysis was higher in patients treated with plasma exchange, a procedure that removes harmful antibodies from the blood. The authors suggest that the need for dialysis at baseline may help identify AAV patients who could benefit most from plasma exchange, though further research is needed to define the target population. These findings may influence future approaches to dialysis initiation and adjunct therapies in AAV-related kidney disease.

Source: ANCA Vasculities



# **Dialysis & Nephrology**

DIGEST

#### Nephrology and Dialysis (cont'd)

SEPTEMBER 23, 2025

### Kidney dialysis equipment market set for strong growth driven by chronic kidney disease

The global kidney dialysis equipment market, valued at \$17.23 billion in 2024, is projected to reach \$27.04 billion by 2031, growing at a CAGR of 6.8%, driven by the rising prevalence of chronic kidney disease (CKD) and end-stage renal disease. Expansion of in-center and home dialysis services, increased screening programs, and government support in emerging markets are boosting demand. Technological advancements, including Al-enabled systems, smart monitoring, wearable hemodialysis devices and biocompatible dialyzers, are improving treatment personalization, patient safety and operational efficiency. North America currently dominates the market, while Asia Pacific is expected to register the highest growth due to aging populations, increased CKD prevalence and heightened awareness of early intervention.

Source: The Insight Partners

## **VAC, ASC and Office-Based Labs**

SEPTEMBER 3, 2025

### Quanta and Innovative Renal Care sign multiyear agreement to expand access to advanced dialysis system

Quanta Dialysis Technologies and Innovative Renal Care (IRC) entered a multiyear strategic partnership to expand use of the Quanta Dialysis System across select IRC programs nationwide. The agreement follows a successful pilot at MercyOne Waterloo Medical Center in lowa, where more than 130 treatments were performed since February 2025, including continuous renal replacement therapy (CRRT) for critically ill patients. Under the deal, IRC will gain access to Quanta's capital equipment, disposables and optional EMR integration to streamline workflows and data monitoring. The Quanta system offers prescription flexibility by supporting CRRT, sustained low efficiency dialysis, and intermittent hemodialysis on a single platform, alongside benefits such as portability, ease of use, reduced maintenance and customizable service models. These features enable IRC to improve care delivery across diverse clinical settings, reduce delays and enhance operational efficiency.

Source: Quanta Dialysis Technologies



#### VAC, ASC and Office-Based Labs (cont'd)

SEPTEMBER 5, 2025

### Florida plan to end vaccine mandates raises legal public health concerns

Florida officials, led by Surgeon General Joseph Ladapo and Governor Ron DeSantis, announced plans to eliminate all state vaccine mandates, including requirements for students, framing the decision as an issue of personal choice. Public health experts warn the move could increase the risk of outbreaks of preventable infectious diseases. While Ladapo said his office will roll back several vaccine mandates under its authority, others remain embedded in state law and would require legislative action when lawmakers reconvene in January. Legal experts suggest potential challenges could arise from parents of disabled or immunocompromised children, teachers' unions, and vaccine advocates, who may argue the policy violates disability protections, due process, or the constitutional right to a safe education.

Source: Reuters (sub. rec.)

#### **SEPTEMBER 15, 2025**

## Renalytix partners with Tempus to expand access to kidneyintelX.dkd testing for CKD patients with type 2 diabetes

Renalytix entered a partnership with Tempus AI to broaden access to its kidneyintelX.dkd prognostic blood test across Tempus' U.S. healthcare network. The test, designed for patients with type 2 diabetes and chronic kidney disease (CKD) stages 1-3b, provides clinicians with risk stratification (high, moderate or low) for progressive kidney function decline. This collaboration marks the first CKD-focused diagnostic in Tempus' portfolio and aims to improve clinical decision-making for a population of nearly 15 million affected Americans. Tests will be processed at Renalytix Laboratories, with results integrated directly into clinician workflows and patient portals to support timely interventions.

Source: Renaltix

#### **OCTOBER 8, 2025**

#### Cigna Temporarily Pauses Its E/M Coding and Accuracy Policy (R49)

Cigna has announced a temporary pause to the implementation of its Evaluation and Management (E/M) Coding and Accuracy Policy (R49), which was initially scheduled to take effect on October 1, 2025. This decision follows significant advocacy from national and state medical associations, including the American Medical Association (AMA), the American College of Allergy, Asthma & Immunology, and the California Medical Association (CMA), as well as ongoing regulatory review by the California Department of Managed Health Care (DMHC).

Source: StreamlineMD



#### VAC, ASC and Office-Based Labs (cont'd)

OCTOBER 10, 2025

## OIG and DOJ Intensify Remote Patient Monitoring Oversight: 2025 Data Snapshot, FCA Settlement and the Emerging Enforcement **Playbook**

Federal oversight of Remote Patient Monitoring (RPM) has entered a new and more aggressive phase. In less than two years, the Office of Inspector General (OIG), the Centers for Medicare & Medicaid Services (CMS), and the Department of Justice (DOJ) have advanced from initial public warnings about fraudulent RPM schemes to a coordinated enforcement posture built on structured oversight recommendations, standardized audit metrics and the first False Claims Act (FCA) settlement involving RPM billing practices.

Source: Benesch

#### OCTOBER 13, 2025

## CMS's IOTA Model Took Effect July 1, 2025: Implications for Transplant Hospitals and Nephrology Stakeholders

On July 1, 2025, the Centers for Medicare & Medicaid Services (CMS), through its Center for Medicare & Medicaid Innovation (CMMI), launched the Increasing Organ Transplant Access (IOTA) Model. This six-year mandatory demonstration will continue through June 30, 2031, and is designed to test whether performance-based incentive payments for kidney transplant hospitals can expand access to transplantation while preserving or enhancing quality of care and reducing Medicare expenditures.

Source: Benesch



#### **Benesch Insights**

#### Jason Greis featured on Wealth Planning for the Modern Physician Podcast

#### "How Practices Can Build the Right Physician Comp Models Today and Beyond"

Host David Mandell welcomes back attorney Jason Greis for his third appearance. Jason, a healthcare business attorney with extensive experience advising physician practices, discusses one of the most pressing issues for independent groups today: physician compensation models and partnership structures. With generational shifts and economic realities reshaping the field, many practices are rethinking what it means to become a partner and how to fairly compensate both younger and senior physicians.



For more information regarding our nephrology, dialysis and office-based lab experience, or if you would like to contribute to the newsletter, please contact:

Jake Cilek | jcilek@beneschlaw.com | 312.624.6363

Scott Downing | sdowning@beneschlaw.com | 312.624.6326

Jason Greis | jgreis@beneschlaw.com | 312.624.6412

## **Advertise with Us!**

To advertise in Benesch's Dialysis & Nephrology Digest, please contact: Lauren Luna at <u>lluna@beneschlaw.com</u> | 216.363.6199 Gillian Stamets at <a href="mailto:gstamets@beneschlaw.com">gstamets@beneschlaw.com</a> | 312.273.5651

